Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Cardiovascular Dynamics

This article was originally published in The Gray Sheet

Executive Summary

Cardiovascular Dynamics: FDA approves PMA supplement for its FACT-22 (Focus Angioplasty Catheter Technology) and ARC-22 (Active Response Catheter) coronary balloon angioplasty catheters. The products feature longer balloon inflation lengths (22 mm), "which expand the clinical applications and potential market" for CVD's Focus technology, the company says. CVD gained approval in January for the original version of its FACT catheter; an original version of the ARC was approved in June. CVD's Focus technology provides users "both low and high balloon inflation pressures within a single catheter," the company says. CVD plans to launch the new FACT-22 and ARC-22 versions at the scientific sessions of the American Heart Association in November...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel